Actively Recruiting
A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis
Led by InventisBio Co., Ltd · Updated on 2026-04-22
222
Participants Needed
1
Research Sites
133 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The target population is patients with active psoriatic arthritis. A total of 222 subjects are planned to be included.
CONDITIONS
Official Title
A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subjects voluntarily agree to participate and sign informed consent
- Male or female aged 18 to 70 years inclusive at consent
- Diagnosed with psoriatic arthritis for at least 3 months before consent
- Active arthritis with at least 3 tender joints and 3 swollen joints
You will not qualify if you...
- History of infection as specified in the protocol
- Presence of any medical diseases or disorders listed in the protocol
- Significant, uncontrolled or unstable disease in any organ
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
West China School of Medicine
Chengdu, Sichuan, China, 610041
Actively Recruiting
Research Team
Y
yi liu, Dr.
CONTACT
C
chen zhong ma
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here